Cell & Gene Therapy
Cell and Gene therapies are life-changing new categories of medicines whose full potential is only just beginning to emerge. They are cutting-edge and rapidly progressing fields of Biological Therapies. Both therapies aim to
treat, prevent or potentially cure diseases and both approaches offer the potential to diminish the fundamental cause of genetic and acquired diseases by substituting the missing protein or cells causing the disease’s symptoms. Cell and gene therapies may offer longer lasting effects than traditional medicines. They are overlapping fields of biomedical research and treatments. However, cell and gene therapies work differently. Cell therapy aims to treat diseases by restoring or altering certain sets of cells or by using cells to carry a therapy through the body while gene therapy treats diseases by replacing, inactivating or introducing genes into cells— either inside the body (in vivo) or outside of the body (ex vivo). Some therapies are considered both cell and gene therapies. These therapies work by modifying genes in specific types of cells and inserting them into the body.
With the promising significance of Cell and Gene therapy, it is poised to transform the healthcare and biopharma industry soon. The market is estimated to increase expeditiously, encompassing sales forecasts of
EUR 27.9 billion by 2026. The development of biological therapies is rapidly expanding, however, it poses different challenges to research and development, authorisation, manufacturing, accessibility, and ensuring safety throughout the lifecycle of the product.
The two-day Congress will provide an interactive, cutting edge, and comprehensive discussions in collaborative format led by key experts with intimate knowledge in the industry. Gain practical strategies and best practices on challenges, innovations, technologies, and concepts to help you gain access to the booming CGT market.
We are putting together an agenda that focuses on “Realising the promises of next generation therapies”.
We are gathering high calibre expert speakers to participate and share their knowledge and expertise through Keynote Presentations and Panel discussions, addressing all aspects of the industry.
We look forward to welcoming you to the CGT World Congress 2023!
GAIN LATEST INSIGHTS ON:
• Clinical Research Organizations
• Research and Development
• Personalised Medicine
• Regenerative Medicine
• External R&D Innovation
• Innovative Medicine
• Rare and Ultra-Rare Diseases
• Cell and Gene Therapy
• Translational Science
• Molecular Geneticist
• Program Management
• Patient and Patient Groups
• Public Affairs
• Medical Affairs
• Regulatory Affairs
• Market Access
• Pricing and Reimbursement
• Health Economics Outcomes Research
• Commercial Development
• Investments and Funding
• Product Specialist
• Global Strategic Services
• Business Planning and Operations
Wenliang Dong, Chief Operating Officer, ORCA Therapeutics B.V.
Alejandro Fernandez-Martell, Former Principal Bioprocess Engineer, Achilles Therapeutics
Doug Danison, Head of Commercial, Cell and Gene Therapy Unit, Bayer
Reagan Jarvis, CEO and Co-founder, Anocca
Zhimei Du, VP, Process Sciences, Atara Biotherapeutics
Eric Halioua, President & Chief Executive Officer, PDC*line Pharma
Mark Singh, Non-Clinical Manager, Cell and Gene Therapy Catapult
Alberto Malerba, Lecturer in Gene Therapy, Royal Holloway University of London
Stephen Judd, Process SME – Biologics / Cell & Gene Therapy, DPS Group
Stuart M Curbishley, Chief Manufacturing and Development Officer, adthera
Manal Morsy, Executive Vice President, Head of Global Regulatory Affairs, Athersys, Inc
Thomas Muller, Head Of Directorate General, Federal Ministry of Health Germany
Julia Djonova, Head, Advanced Therapy Medicinal Products, Swissmedic
Ben Doak, Head of Innovative Treatments, NHS England
Dr Matthias Bozza, Director, Vector Biopharma AG
Francois Hallac, Research Associate, King’s College London
Nick Forsyth, Faculty Dean of Research, Keele University
Dr. Anand Srivastava, Chairman and Co-founder, Global Institute of Stem Cell Therapy and
Mohamed Oubihi, Founder and CEO, YAKUMED
– Dealing with surrogate endpoints
– Modifications & Flexibilities for Evaluation of Rare Diseases)
– Gene Therpaies
– Cellular Therapies
– Aduhelm & Leqembi (not gene therapies… but relevant for general understanding)
Eugean Jiwanmall, Senior Research Analyst, Independence Blue Cross
Chris Williams, SVP Corporate Development, Autolus Ltd.
Stefanos Theoharis, Independent Expert
No Spam - You will only receive relevant information on Cell & Gene Therapy, and events updates.
Take Advantage of the Super Early Bird Discount. Group Discounts Also Available.